Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$83.22M+268351.61%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kevin C. Tang
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 128
- Beta
- 1.41
- Country
- CA
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 7.63
Financials
Revenue
$83.22M+268351.6%Net Income
$37.41MEBITDA
$54.57MFree Cash Flow
$52.17MEPS (diluted)
$0.28Shares Outstanding (diluted)
133.53M+270.1%Operating Expenses
$36.56MCash & Debt
$443.12MReturn of Capital
$38.37MRevenue by Segment (annual)
$283.06MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $283.06M | $287.20M | $2.14 |
| 2024 | $235.13M | $5.75M | $0.04 |
| 2023 | $175.51M | $-78.02M | $-0.54 |
| 2022 | $134.03M | $-108.18M | $-0.76 |
| 2021 | $45.60M | $-180.97M | $-1.40 |
| 2020 | $50.12M | $-102.68M | $-0.87 |
| 2019 | $318.0K | $-88.39M | $-1.33 |
| 2018 | $463.0K | $-64.12M | $-0.76 |
| 2017 | $420.0K | $-70.79M | $-0.92 |
| 2016 | $173.0K | $-23.30M | $-0.66 |
| 2015 | $235.0K | $-18.61M | $-0.58 |
| 2014 | $278.0K | $-16.65M | $-0.57 |
| 2013 | $948.6K | $-2.55M | $-0.40 |
| 2012 | $6.16M | $-9.74M | $-2.74 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.14
- Implied price
- $21.98
- Return from $15.74
- 6.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $10.93 — -30.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 3 | 5 | 7 | 9 | 11 |
|---|---|---|---|---|---|
| -2.0% | -18.1% | -9.3% | -3.0% | 2.0% | 6.2% |
| 3.0% | -13.9% | -4.7% | 2.0% | 7.2% | 11.6% |
| 8.0% | -9.8% | -0.1% | 6.9% | 12.4% | 17.0% |
| 13.0% | -5.6% | 4.6% | 11.9% | 17.6% | 22.4% |
| 18.0% | -1.4% | 9.2% | 16.8% | 22.8% | 27.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
135+1250.00%Social Signal Score
Mentions (3)
- Newszacks.com·46d ago·Neutral
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.
View source ↗ - Newsbenzinga.com·47d ago·Negative
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday's premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).
View source ↗ - Newsseekingalpha.com·54d ago·Negative
Aurinia Pharmaceuticals Doubles Down On Its Pipeline Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its market exclusivity in the not-too-distant future. AUPH is developing aritinercept in four potential indications but doesn't provide much clarity on timelines for further updates.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $0.22 per share
Typical surprise +23.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.28 vs $0.24beat
- Thu, May 7$0.25 vs $0.18beat
- Thu, Feb 26$0.26 vs $0.21beat
- Tue, Nov 4$0.23 vs $0.16beat
- Thu, Jul 31$0.16 vs $0.17miss
- Mon, May 12$0.16 vs $0.08beat
Estimates and results for AUPH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AUPH officers and directors.
- Bought
- $62.3m
- Sold
- $6.7m
23 trades
13 trades
- Robertson Stephen P.sold
- Robertson Stephen P.sold
- Tang Kevinboughtdirector, 10 percent owner, officer: Chief Executive Officer·206,005 @ $15.28·$3.1m·Jun 2, 2026·filing
- Tang Kevinbought
- Tang Kevinboughtdirector, 10 percent owner, officer: Chief Executive Officer·343,521 @ $15.28·$5.2m·Jun 1, 2026·filing
- Tang Kevinboughtdirector, 10 percent owner, officer: Chief Executive Officer·262,682 @ $15.31·$4.0m·May 29, 2026·filing
- Tang Kevinboughtdirector, 10 percent owner, officer: Chief Executive Officer·2,299 @ $15.35·$35k·May 29, 2026·filing
- Tang Kevinbought
64 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AUPH.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.